Tuesday, January 3, 2017
AbbVie: Humira’s patent maze will keep US biosimilars away until at least 2022
AbbVie: Humira’s patent maze will keep US biosimilars away until at least 2022: Humira's extensive estate of over 70 formulation, manufacturing and method of treatment patents will keep US competition at bay until at least 2022, says AbbVie.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment